Patients who developed spinal metastases were significantly more likely to have an EGFR mutation in the primary tumor compared to those who did not develop spinal metastases, which could be explained by increased survival in the EGFR mutated tumors due to targeted therapies. The gene discussed is EGFR; the disease is neoplasm.